Latest from MD Anderson

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.
Hagop Kantarjian, MD, discusses the success of blinatumomab and next steps with the anti-CD19 agent.
Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with anaplastic thyroid cancer.
Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.
John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.
Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses why researchers and physicians should reconsider the utility of PD-L1 as a biomarker for patients with bladder cancer.
Brian F. Chapin, MD, discusses the importance of active surveillance in patients with prostate cancer at a low risk of developing metastases and the benefits of surgery and radiation as active treatment methods for patients with locally advanced disease.
Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the agents available to treat patients with metastatic castration-resistant prostate cancer (mCRPC)
Publication Bottom Border
Border Publication